In the phase 3 study Checkmate 816, the arm of nivolumab and doublet of platinum-based chemotherapy showed an increase in the percentage of patients undergoing definitive surgery from 75 to 83%, and improvement in Pathologic Complete Response (PCR) rate from 2.2 to 24.0%, OR 13.94 (CI 3.49–55.75) P < 0.0001 as well as major pathological response MPR (37% vs 9%), independent of clinical stage, PD-L1 levels or mutational tumor burden (TMB) [15]. Here, CD274 is linked to neoplasm.